Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Inclusion criteria (MRA011JP patients) * Of the patients who received the three infusions of MRA at the same dose in the main evaluation period in the previous study and are currently in the continued treatment period * the patients in whom it is confirmed that the drug is effective and there are no problems with safety (MRA316JP patients) * Patients who proceed to the blind period and in whom the last observations are done after study completion or withdrawal * Patients who receive the three infusions in the open-label period and do not meet the criteria for transition to the blind period Exclusion criteria * Patients who were not enrolled by 3 months after completion of the previous study * Patients who have been treated with infliximab or etanercept from completion of the previous study until the start of treatment in this study